Emcure Pharmaceuticals Ltd Share Price

Pharmaceuticals

NSE: EMCURE Small Cap ISIN: INE168P01015

As on 18 November 2025 at 23:55 IST

₹1,343.30

-50.80

(-3.64%)

Sell Buy

Emcure Pharmaceuticals Q1 FY26 Results:

Net profit rose 44% to ₹207 crores, compared to ₹144 crores in Q1 FY25. Total income in Q1 FY26 increased 14.5% to ₹2,104 crores from ₹1,838 crores in the same period last year.

About Emcure Pharmaceuticals Ltd

Emcure Pharmaceuticals Ltd is a leading Indian multinational pharmaceutical company. The company is engaged in developing, manufacturing, and marketing a broad range of pharmaceutical products. It operates in the pharmaceutical sector. The company was founded in the year 1981 by Satish Mehta, making it many years old. The headquarters of Emcure Pharmaceuticals is located in Hinjewadi, Pune, India. Emcure’s main products span several therapeutic areas. These include gynecology, cardiovascular, oncology, HIV antivirals, and vitamins and minerals. The company is known for its innovative approach to developing biologics and mRNA vaccines. +

Over 1 Month

3.46%

Over 6 Months

29.56%

Over 1 Year

6.81%

Over 3 Years

None%

Emcure Pharmaceuticals Ltd Summary

Close ₹1,394.10

Open ₹1,380.30

High ₹1,447.60

Low ₹1,371

Volume 4,78,379

Net Turnover (in Cr) ₹67.63

52Wk High ₹1,519.90

52Wk Low ₹889

52Wk High / Low

889

1,519.90

Emcure Pharmaceuticals Ltd Fundamentals

Key Financial Data

Market Cap (in Cr) ₹26,427.24

EPS (TTM) 22.83

Book Value (BV) 169.51

Div. Yield 0.21 %

P/E (TTM) 61.50

Price/Book Value 8.23

Delivery % 49.38 %

Face Value 10

Key Ratios

PE Ratio 64.09

PB Ratio 6.72

EV to Sales 4.83

PEG Ratio 0.72

ROA 8.05

ROE 12.79

Debt-Equity 0.49

Net Profit Margin 7.24

Operating Profit Margin 17.47

Emcure Pharmaceuticals Ltd Financials

Consolidated

Standalone

Yearly

Quarterly

Profit and Loss

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	7,968.78	6,715.24	6,031.72	5,918.86	5,067.35
Total Expenses	6,987.06	5,978.08	5,278.35	4,946.31	4,222.13
Profit Before Tax	971.35	727.23	747.22	972.55	840.70
Profit After Tax	707.47	527.58	561.85	702.56	607.25
Operating Profit After Depreciation	1,157.51	974.31	966.97	1,148.53	1,000.16

Balance Sheet

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Fixed Assets	3,250.07	3,151.32	2,154.77	2,054.41	2,267.97
Total Non Current Assets	3,676.86	3,546.25	2,836.62	2,639.37	3,089.95
Total Current Assets	4,555.86	4,259.91	3,835.91	3,424.10	3,717.45
Total Assets	8,232.72	7,806.16	6,672.53	6,063.47	6,807.40
Total Shareholder's Fund	4,446.19	2,952.28	2,501.13	1,987.55	2,273.02

Cash Flow

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash From Operating Activities	851.71	1,097.24	746.85	768.21	704.44
Net Cash Used In Investing Activities	-96.05	-714.51	-467.81	-574.49	-256.47
Net Cash Used In Financing Activities	-813.96	-164.21	-145.40	-151.85	-188.90

Profit and Loss

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	4,524.40	3,635.91	3,232.43	3,519.92	3,265.57
Total Expenses	4,096.69	3,426.68	3,013.95	2,903.50	2,689.84
Profit Before Tax	427.71	199.91	212.34	616.42	557.45
Profit After Tax	317.13	160.83	160.06	446.81	420.48
Operating Profit After Depreciation	540.67	375.32	385.32	761.56	699.08

Balance Sheet

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Fixed Assets	1,765.34	1,718.24	1,268.20	1,151.48	1,277.90
Total Non Current Assets	2,956.06	2,633.50	2,456.44	2,181.55	2,647.74
Total Current Assets	2,460.05	2,123.43	2,159.41	2,141.63	2,215.46
Total Assets	5,416.11	4,756.93	4,615.85	4,323.18	4,863.20
Total Shareholder's Fund	3,024.36	1,935.10	1,841.87	1,712.53	2,301.77

Cash Flow

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash From Operating Activities	558.29	584.97	505.37	427.71	774.87
Net Cash Used In Investing Activities	-437.66	-173.08	-270.56	-393.81	-835.78
Net Cash Used In Financing Activities	-49.25	-287.75	-54.52	-342.96	30.97

Particulars (in ₹ Cr.)	2025-09	2025-06	2025-03	2024-12	2024-09
Total Revenue	2,269.82	2,100.54	2,116.25	1,962.63	2,001.98
Total Expenses	1,794.35	1,683.76	1,713.84	1,600.88	1,621.11
Profit Before Tax	341.41	290.76	260.61	229.92	273.40
Profit After Tax	251.37	214.79	197.24	156.09	201.55
Operating Profit after Depreciation	478.59	420.48	406.86	358.51	416.52

Particulars (in ₹ Cr.)	2025-09	2025-06	2025-03	2024-12	2024-09
Total Revenue	1,260.60	1,096.57	1,278.19	1,028.81	1,104.63
Total Expenses	1,036.01	868.57	1,033.55	911.51	946.59
Profit Before Tax	157.89	165.66	186.06	67.24	119.36
Profit After Tax	117.62	122.79	139.56	50.20	86.92
Operating Profit after Depreciation	247.34	249.52	267.04	143.82	207.10

Emcure Pharmaceuticals Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 1,360.87

S2 1,327.63

S3 1,284.27

Pivot 1,404.23

R1 1,437.47

R2 1,480.83

R3 1,514.07

Moving Average

20 SMA 1,359.07

50 SMA 1,355.12

100 SMA 1,366.91

200 SMA 1,238.49

Emcure Pharmaceuticals Ltd Corporate Actions

Emcure Pharmaceuticals Ltd

₹3.0/Share

Announcement Date 14 Aug 2025

Record Date 14 Aug 2025

Div Yield 30%

Emcure Pharmaceuticals Ltd Peer Comparison

Company	Price	Market Cap (in Cr)
Sun Pharmaceutical Industries Ltd	₹1,763.70	₹4,23,170.71
Divis Laboratories Ltd	₹6,523.25	₹1,73,171.79
Torrent Pharmaceuticals Ltd	₹3,816.75	₹1,29,170.36
Cipla Ltd	₹1,536.25	₹1,24,093.85
Dr Reddys Laboratories Ltd	₹1,244.50	₹1,03,868.61

Emcure Pharmaceuticals Ltd Top Mutal Funds Invested

Fund Name	AUM
DSP Healthcare Fund	1.65%
ICICI Pru P.H.D Fund	0.91%
Aditya Birla SL ELSS Tax Saver Fund	0.89%
Aditya Birla SL Multi-Cap Fund	0.86%
Nippon India Pharma Fund	0.74%

Emcure Pharmaceuticals Ltd News

Novo Nordisk India partners with Emcure launch Poviztra' in India

10 Nov 2025, 12:51 pm

Emcure Pharmaceuticals to hold board meeting

On 11 November 2025

04 Nov 2025, 03:07 pm

Emcure Pharmaceuticals' Kadu unit clears USFDA inspection

10 Oct 2025, 02:43 pm

Emcure Pharmaceuticals to hold AGM

On 28 August 2025

02 Aug 2025, 02:15 pm

Emcure Pharmaceuticals to discuss results

On 7 August 2025

29 Jul 2025, 10:54 am

Emcure Pharmaceuticals Ltd Stock Analysis

Annual revenue for Emcure Pharmaceuticals Ltd increased by 24.44% to ₹4,524.40 crore in FY 2025 from ₹3,635.91 crore in FY 2024.
Annual Net Profit for Emcure Pharmaceuticals Ltd increased by 97.18% to ₹317.13 crore in FY 2025 from ₹160.83 crore in FY 2024.
Promoter Shareholding in Emcure Pharmaceuticals Ltd decreased by 0.04% in the most recent quarter, from 77.91% in June 2025 to 77.88% in September 2025.
Emcure Pharmaceuticals Ltd delivered a 1-year return of 6.81% compared to the Nifty 50, which provided a return of 10.91% as of the last trading session.
Emcure Pharmaceuticals Ltd share price moved down by 3.64% from its previous close of INR ₹1,394.10. The latest Emcure Pharmaceuticals Ltd share price is INR ₹1,343.30.
Emcure Pharmaceuticals Ltd share price today has been at a low of 1,326 and a high of 1,359.20. Over the past 52 weeks, the Emcure Pharmaceuticals Ltd share price has seen a low of 889 and a high of 1,519.90.

About Emcure Pharmaceuticals Ltd

Emcure Pharmaceuticals Ltd is a leading Indian multinational pharmaceutical company. The company is engaged in developing and manufacturing a broad range of pharmaceutical products. It also focuses on marketing these products. Emcure’s product portfolio includes tablets, capsules, injectables, and biologics. These products cater to various therapeutic areas, such as gynecology and anti-infectives.
It has established itself as a significant player in the pharmaceutical sector. The company is recognized for its contributions to the industry. The company was founded in 1981 by Satish Mehta. Over the decades, Emcure has grown substantially, expanding its presence to over 70 countries worldwide.
The headquarters of Emcure Pharmaceuticals is located in Hinjawadi, Pune, India. The company's promoters include Satish R Mehta, with a 39.87% stake. He is also the CEO and Managing Director, Berjis Desai is the Chairman, and Namita Thapar is the Executive Director. A team of professional managerial promoters manages the operations of the company-

Berjis Minoo Desai
Sunil Rajanikant Mehta
Samit Satish Mehta

Emcure’s main products span several therapeutic areas. These include gynecology, cardiovascular, oncology, HIV antivirals, and vitamins and minerals. The company is known for its innovative approach to developing biologics and mRNA vaccines. Emcure’s commitment to research and development is evident in its robust pipeline of new products and formulations.
While Emcure Pharmaceuticals is a significant player in the Indian pharmaceutical industry, it is not the largest. It ranks below others in terms of market share and market capitalization. However, it is ranked India's 12th largest pharmaceutical company as of June 2024. This ranking highlights its significant presence and influence in the market. The registered office of Emcure Pharmaceuticals is located in Pune, Maharashtra. Additionally, the registrar's office is situated in Mumbai, Maharashtra.

Impact of Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Ltd has made a significant impact on the global pharmaceutical industry. Founded in 1981, the company has become a key player in pharmaceutical manufacturing. It also focuses on marketing a wide range of these products. Emcure’s influence extends across various therapeutic areas. These include gynecology, cardiology, oncology, and anti-infectives. This broad portfolio has allowed the company to address numerous health challenges and improve patient outcomes worldwide.
One of the most notable impacts of Emcure Pharmaceuticals is its contribution to the accessibility of essential medicines. The company has a strong presence in over 70 countries, ensuring its products reach a diverse and widespread population. Emcure’s commitment to affordability and accessibility has enabled many people, especially in developing countries, to access high-quality medications. This focus on accessibility aligns with the company’s mission to enhance global health and well-being.
Emcure’s impact is also evident in its innovative approach to pharmaceutical development. The company invests heavily in research and development, leading to the creation of new and effective treatments. Emcure has been at the forefront of developing biologics and mRNA vaccines. These innovations are crucial in the fight against various diseases. This dedication ensures that Emcure remains a leader in the pharmaceutical industry. The company continuously offers advanced solutions to meet evolving healthcare needs.
Emcure Pharmaceuticals has also played a vital role in the fight against HIV/AIDS. The company produces a range of antiretroviral drugs that are essential in managing HIV infection. These medications have been instrumental in improving the lives of people living with HIV. They help reduce viral load and prevent the progression of the disease. Emcure’s contributions highlight its commitment to tackling global health crises. The company also supports vulnerable populations through its efforts.
The company’s impact is not limited to its products alone. Emcure is also known for its corporate social responsibility initiatives. The company engages in various activities aimed at improving community health and well-being. These initiatives include health camps, educational programs, and environmental sustainability projects. Emcure’s focus on social responsibility reflects its belief that businesses have a role in creating a better world.
Its strong leadership and management team further amplifies Emcure’s influence. The company’s founder, Satish Mehta, has been a driving force behind its growth and success. Under his leadership, Emcure has expanded its operations and established a strong presence in the global market. The management team’s vision and strategic direction have been crucial for navigating the challenges of the pharmaceutical industry. They have also played a significant role in achieving sustained growth.
The company’s impact on the pharmaceutical industry is also reflected in its financial performance. Emcure has consistently demonstrated strong financial results. This success has enabled the company to reinvest in research and development. This financial stability has allowed the company to pursue ambitious projects. It has also enabled the expansion of its product portfolio. Emcure’s robust financial health is a testament to its effective business strategies and operational excellence.
Emcure Pharmaceuticals has also made significant contributions to the local economy. The company provides employment opportunities to thousands of people, supporting livelihoods and contributing to economic development. Emcure’s operations have a positive ripple effect on the communities where it operates, fostering economic growth and stability.